• Home
  • About Us
    • AdAlta at a glance
    • Board
    • Management Team
  • Cancer Cell Therapies
    • “East to West” strategy
    • “East to West” product pipeline
  • I-Body Therapeutics
    • i-bodies
    • AD-214: A new approach to fibrotic disease
    • Fibrosis
  • Investors
    • Annual and Financial Reports
    • Presentations
    • Analyst Reports
    • ASX Announcements
    • News & Media
    • Corporate Governance
  • Contact Us

..Author: IRM Support

Becoming a substantial holder

August 24, 2016

Becoming a substantial holder

August 24, 2016

Becoming a substantial holder

August 24, 2016

Becoming a substantial holder

August 24, 2016

Investor Presentation

August 24, 2016

AdAlta IPO to Accelerate New Therapy for Lung Fibrosis

August 24, 2016

Initial Director’s Interest Notice

August 24, 2016

Initial Director’s Interest Notice

August 24, 2016

Initial Director’s Interest Notice

August 24, 2016

Initial Director’s Interest Notice

August 24, 2016

Posts navigation

Older posts
Newer posts

Archives

2016 News

  • Initial Director’s Interest Notice
  • AdAlta Extends Board with Appointment of US-Based Non Executive Director
  • Director Appointment
  • Results of AdAlta AGM 2016
  • AGM Presentation

2015 News

  • AdAlta and The University of Melbourne to develop i-bodies for the treatment of various eye diseases
  • Japanese patent granted for AdAlta i-body technology
  • AdAlta appoints Dr Paul MacLeman Chairman
  • AdAlta expands its scientific advisory team

2014 News

  • AdAlta expands its scientific advisory team
  • Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics

2013 News

  • AdAlta collaborates with Crossbeta to find i-body for Alzheimer’s disease
  • AdAlta awarded voucher to explore benefits of technologies with Ferring Research Institute

2012 News

  • AdAlta and Baker IDI sign agreement to identify i-bodies to anti-thrombotic target
  • AdAlta and Roche sign agreement to evaluate shark antibody technology

2011 News

  • US patent granted for AdAlta i-body technology
  • AdAlta receives VC investment from Perth-based Yuuwa Capital

© 2025 AdAlta Limited Disclaimer | Privacy Policy
© 2016 AdAlta Limited